Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Circio Holding ASA

Market Cap 1.94B 205M 177M 163M 152M 286M 19.46B 290M 1.92B 750M 9.47B 768M 752M 32.79B P/E Ratio 2026 *
-
P/E Ratio 2027 * -
Enterprise Value 1.94B 205M 177M 163M 152M 286M 19.46B 290M 1.92B 750M 9.47B 768M 752M 32.79B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
69.39%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Circio Holding ASA

1 day+0.61%
1 week+0.49%
Current month-8.78%
1 month-26.17%
3 months+43.78%
6 months+549.53%
Current year+605.33%
1 week 7.3
Extreme 7.3
8.72
1 month 7.3
Extreme 7.3
11.56
Current year 0.98
Extreme 0.978
14.46
1 year 0.55
Extreme 0.547
14.46
3 years 0.48
Extreme 0.48
20.97
5 years 0.48
Extreme 0.48
274.5
10 years 0.48
Extreme 0.48
1,017
Manager TitleAgeSince
Chief Executive Officer - 20/10/2021
Director of Finance/CFO 58 07/03/2022
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 79 01/07/2015
Director/Board Member 66 14/09/2015
Chairman 64 29/04/2020
Date Insider Type Main position Quantity % Market Cap.
30/11/21Fiscal year

Chief Executive Officer

120,000 0.1386%
19/05/21Buy

Director

21,299 0.0246%
03/12/20Buy

Chief Technology Officer

10,000 0.0116%
Change 5-day change 1-year change 3-year change Capi.($)
+0.61%+0.49%+1,163.08%-60.85% 205M
-2.25%+0.34%+58.52%+112.25% 56.42B
+2.72%+3.26%+46.05%+47.37% 44.54B
+1.18%+7.26%-13.75%-18.84% 22.9B
+0.02%+5.48%-2.22%+396.40% 21.21B
-0.51%+1.78%+16.68%-34.63% 16.4B
-1.36%-0.90%+8.27%-39.18% 15.4B
-1.12%+1.97%+26.37%+176.23% 13.35B
+0.96%+9.74%+17.55% - 12.36B
+1.61%+1.28%+95.75%+206.59% 11.15B
Average +0.18%+1.57%+141.63%+87.26% 21.39B
Weighted average by Cap. +0.02%+2.36%+33.97%+98.69%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Circio Holding ASA
Circio Holding ASA, formerly Targovax ASA, is a Norway-based company active within the healthcare sector. The Company is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The Company offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio’s second clinical program is an immunotherapy targeting KRAS driver mutations.
Employees
10
Date Price Change Volume
15/06/26 8.210 kr +0.61% 2,193,227
12/06/26 8.160 kr +9.09% 7,624,359
11/06/26 7.480 kr -6.85% 7,789,340
10/06/26 8.030 kr -3.72% 5,950,424
09/06/26 8.340 kr +2.08% 4,982,754

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRNA Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!